JPRN-UMIN000000947未知未知
Reversal of diabetes and prevention of arteriosclerosis in type 2 diabetic patients with oral antidiabetic agents - Pioglitazone and Sulfonylurea Remission from T2DM development and anti-atherosclerosis in Japan : PREVENT-J
PREVENT-J Study Steering Committee0 个研究点目标入组 500 人开始时间: 2007年12月14日最近更新:
适应症
试验速览
- 阶段
- 未知
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •-Heart failure or history of heart failure. -EF of less than 40%. -History of adverse reactions to a thiazolidine derivative or concerns about safety. -Severe hepatic dysfunction. -Severe renal dysfunction. -History of cardiovascular disease. -Current treatment with a sulfonylurea drug. -Current treatment with a thiazolidine derivative. -Current treatment with insulin. -Those whom the principle investigator or other investigators consider unsuitable.
研究者
相似试验
已完成
2 期
Anti-platelet therapy for prevention of diabetic nephropathydiabetic nephropathyJPRN-UMIN000007718ational Hospital Organization Headquarters150
进行中（未招募）
3 期
Metformin treatment for diabetes prevention in AfricaISRCTN77382043niversity College London2,100
已完成
不适用
A project to prevent the worsening of diabetic nephropathy in Kure city: A study of the effectiveness of the program to prevent the aggravation of CKDchronic kidney diseaseJPRN-UMIN000012407Hiroshima University, Graduate School of Biomedical and Health Sciences41
进行中（未招募）
不适用
Religious leaders and diabetes prevention in BangladeshPrevention of diabetesNutritional, Metabolic, EndocrineISRCTN91564707Ministry of Health and Family Welfare824
进行中（未招募）
不适用
Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects with Metabolic Syndrome and High-Normal Blood Pressure. - PHIDIASHypertension, diabetes mellitus.MedDRA version: 6.1Level: SOCClassification code 10007541EUCTR2007-000947-88-ITISTITUTO AUXOLOGICO ITALIANO6,000